ProteinQure Unveils Breakthrough Peptide Drug Conjugate for Triple-Negative Breast Cancer

ProteinQure, a startup at the forefront of peptide drug design, has announced a significant discovery in the battle against triple-negative breast cancer (TNBC). Their innovative Peptide Drug Conjugate (PDC), leveraging advanced computational techniques, shows exceptional efficacy in Patient-Derived Xenograft (PDX) models. This development took place in collaboration with Dr. David Cescon's lab at the Princess Margaret Cancer Centre, a leading cancer research facility.

The PDC targets SORT1 with a novel peptide linked to a potent chemotherapeutic agent, exhibiting unprecedented anti-tumor effects, even in cancers that resist conventional treatments. Lucas Siow, CEO of ProteinQure, expressed that the collaboration and subsequent findings are pivotal for advancing their lead program into clinical trials, showcasing the promise of their computational drug design platform in creating targeted tissue-specific peptides.

These groundbreaking results are slated for presentation at the American Association for Cancer Research (AACR) conference in San Diego, indicating a significant step forward in developing new therapies for challenging cancer forms like TNBC. The project received support from funding entities including IRAP-Canada and the INOVAIT program, demonstrating a collective effort in fostering innovative cancer treatment solutions.